Skip to main content

Table 4 Results using different normal organ dose limits for subject #8

From: Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

  Organ dose limits Maximum activity (GBq)90Y-DOTA alone (given over multiple cycles) Optimum percentage of maximum90Y activity to be given when adding MIBG Acivity (GBq) of131I-MIBG that can be added without exceeding limits Tumor dose (cGy):90Y-DOTA given alone Tumor dose (cGy):90Y + 131I
Kidney 2,300 4.9 75 33.3 1,006 2,499
Marrow 300
Kidney 2,300 4.9 87 17.6 1,006 1,794
Marrow 200
Kidney 2,700 5.8 80 30.8 1,180 2,565
Marrow 300